In DepthDRUG DEVELOPMENT

New drugs target growing threat of fatal fungi

See allHide authors and affiliations

Science  25 Oct 2019:
Vol. 366, Issue 6464, pp. 407
DOI: 10.1126/science.366.6464.407

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

An estimated 1.5 million people die worldwide every year of invasive fungal diseases. Although there are some drugs available to fight these infections, doctors have long said more are needed. The urgency is growing, as cases have increased and once-treatable fungi are becoming resistant. Now, a slew of new drugs—several of them establishing new classes of antifungals—are making their way through clinical testing including olorofim, which blocks the synthesis of pyrimidine, the precursor of DNA building blocks, and fosmanogepix, a new broad-spectrum antifungal that received "fast-track" status from the U.S. Food and Drug Administration last month. Even if these drugs make it to the market, however, new diagnostics are also needed for the drugs to have the maximum impact.

View Full Text